Tri-Agency Oncology Biomarker Initiative Commences With PET Scan Study
Executive Summary
Oncology biomarker qualification efforts jointly tackled by FDA, the National Cancer Institute and CMS will encompass prospective studies and ongoing clinical trials
You may also be interested in...
FDA, CMS Joint Guidance On Studies Using Cancer Biomarkers Sought In Bill
FDA and CMS are directed to jointly develop guidelines on clinical studies relating to cancer care and treatment biomarkers in legislation (S. 717) introduced by Sens. Ted Kennedy, D-Mass., and Kay Bailey Hutchinson, R-Texas, on March 26
FDA, CMS Joint Guidance On Studies Using Cancer Biomarkers Sought In Bill
FDA and CMS are directed to jointly develop guidelines on clinical studies relating to cancer care and treatment biomarkers in legislation (S. 717) introduced by Sens. Ted Kennedy, D-Mass., and Kay Bailey Hutchinson, R-Texas, on March 26
“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development